Latest Breaking News On - Exelixi annual report - Page 3 : comparemela.com

Stock Market | FinancialContent Business Page

Stock Market | FinancialContent Business Page
financialcontent.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialcontent.com Daily Mail and Mail on Sunday newspapers.

Chris sennerJoele frankTomas heymanRobert oliverWilkinson brimmer katcherSusan hubbardJamie moser sharonExelixis incPublic affairs investor relationsExchange commissionCapital allocation committeeFarallon capitalFarallon capital managementExecuting strategyBalanced capitalCapital allocation

Exelixis Announces $550 Million Share Repurchase Program

20.03.2023 - Exelixis, Inc. (Nasdaq: EXEL) today announced that the company’s Board of Directors has authorized the repurchase of up to $550 million of the company’s common stock before the end of 2023. The timing and amount of any share repurchases under the .

Exchange commissionExelixis incExelixi annual report

Exelixis, Inc : Exelixis and Sairopa Announce US FDA Clears Investigational New Drug Application for ADU-1805 in Patients with Advanced Solid Tumors

- ADU-1805 is a potential best-in-class monoclonal antibody targeting SIRPa to block the SIRPa-CD47 checkpoint - - Phase 1 study of ADU-1805 as a single agent and in a combination regimen in advanced

Laura lassouw polmanSairopabv sairopaGurvinder singh chahalStekki millmanDharminder singh chahalSusan hubbardVickil goodmanDrug administrationExchange commissionExelixis incPublic affairsProduct development medical affairsChinook therapeutics incInvestigational new drugInvestigational new drug applicationExecutive vice president

Exelixis (EXEL) and Bristol Myers Squibb (BMY) Reports Strong Results from Phase 3 CheckMate-9ER Trial

Exelixis (EXEL) and Bristol Myers Squibb (BMY) Reports Strong Results from Phase 3 CheckMate-9ER Trial
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSouth koreaDana walkerClaire mcconnaugheyMauricio burottoSusan hubbardBristol myers squibbVickil goodmanCompany opdivoAmerican society of clinical oncologyTakeda pharmaceutical companyExelixis incPublic affairsProduct development medical affairsEuropean unionBradford hill clinical research center

Exelixis, Inc : Exelixis Partner Ipsen Receives European Commission Approval for CABOMETYX (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer

- Approval is based on COSMIC-311 trial, in which CABOMETYX demonstrated significant improvement in progression-free survival versus placebo - Exelixis, Inc. (Nasdaq: EXEL) today announced that

United statesSusan hubbardVickil goodmanLindsay treadwayDaiichi sankyo companyEuropean commissionDrug administrationGenentech incBristol myers squibb companyTakeda pharmaceutical companyExchange commissionProduct developmentExelixis incPublic affairsEuropean unionAmerican cancer society